BioSpace News Archive

Xeris Biopharma Holdings, Inc. today announced it has entered into a senior secured term loan agreement (“debt facility”) with funds managed by Hayfin Capital Management LLP (“Hayfin”) to provide Xeris with up to a total of $150 million of capital.

Cingulate Inc. today announced its financial results for the three and 12 months ended December 31, 2021, and provided a clinical and business update.

Oncorus, Inc. announced that President and Chief Executive Officer, Theodore Ashburn, M.D., Ph.D., will present at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 4:40 p.m. ET.

TherapeuticsMD, Inc. today reported financial results for the fourth quarter ended December 31, 2021.

Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced the appointment of Aaron Tward, M.D., Ph.D., as chief scientific officer.

Baudax Bio, Inc. announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 2:40 p.m. Eastern Time.

TRACON Pharmaceuticals (Nasdaq: TCON), today announced that the first patient has been dosed following the approval of the amended ENVASARC protocol by the U.S. Food and Drug Administration (“FDA”).

RAPT Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2021.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has submitted a Scientific Advice Briefing Document with the European Medicines Agency (EMA) for QRX003, the Company’s investigational treatment for Netherton Syndrome.

Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), announced today that results from the US Phase 3 pivotal Cardigan I and Cardigan II studies of sofpironium bromide gel, 15% in primary axillary hyperhidrosis patients were selected for an oral presentation at the Late-Breaking Research session during the American Academy of Dermatology’s (AAD) 2022 Annual Meeting.